LY3016859 + Placebo
Phase 2Completed 0 watching 0 views this week⚡ Active
52
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Diabetic Peripheral Neuropathic Pain
Conditions
Diabetic Peripheral Neuropathic Pain
Trial Timeline
Jul 15, 2020 → Nov 11, 2021
NCT ID
NCT04476108About LY3016859 + Placebo
LY3016859 + Placebo is a phase 2 stage product being developed by Eli Lilly for Diabetic Peripheral Neuropathic Pain. The current trial status is completed. This product is registered under clinical trial identifier NCT04476108. Target conditions include Diabetic Peripheral Neuropathic Pain.
Hype Score Breakdown
Clinical
17
Activity
12
Company
10
Novelty
5
Community
5
Clinical Trials (3)
| NCT ID | Phase | Status |
|---|---|---|
| NCT04529096 | Phase 2 | Completed |
| NCT04476108 | Phase 2 | Completed |
| NCT04456686 | Phase 2 | Completed |
Competing Products
20 competing products in Diabetic Peripheral Neuropathic Pain